Q2 2024 Axsome Therapeutics Inc Earnings Call Transcript
Key Points
- Axsome Therapeutics Inc (AXSM) reported strong commercial performance with significant growth in product sales, particularly for ABILITY, which saw a 135% year-over-year increase.
- The company made substantial progress in its late-stage development pipeline, with pivotal trial readouts expected later this year for multiple indications.
- Axsome Therapeutics Inc (AXSM) successfully expanded payer coverage for ABILITY, increasing the percentage of covered commercial lives from 48% to 60%.
- The company has a robust cash position, ending the second quarter with $315.7 million in cash and cash equivalents, which is sufficient to fund anticipated operations into cash flow positivity.
- Axsome Therapeutics Inc (AXSM) is advancing its NDA submissions for AXS-07 for acute migraine treatment and AXS-14 for fibromyalgia, with expected updates on FDA reviews and submissions in the near term.
- The company reported a net loss of $79.3 million for the second quarter of 2024, an increase from the $67.2 million net loss in the same period in 2023.
- Research and development expenses significantly increased to $49.9 million, primarily due to the initiation and continuation of multiple Phase 3 trials.
- Selling, general, and administrative expenses rose to $103.6 million, driven by commercialization expenses and field force expansion.
- Gross-to-net discounts for both ABILITY and Sunosi were in the low to mid-50s, indicating substantial deductions from gross sales.
- The company faces challenges in the competitive landscape for its products, particularly in the crowded migraine treatment market and the payer dynamics for new product launches.
Hello, and welcome to the Axsome Therapeutics Second Quarter 2024 financial results conference call and webcast. At this time, all participants are in the listen only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. You may be placed in the question queue at any time by pressing star one on your telephone keypad. We ask you please limit yourselves to one question then return to the queue. As a reminder, this conference is being recorded is now my pleasure to turn the call over to Darren open, Director of Corporate Communications at Axsome Therapeutics. Please go ahead, Darren.
Good morning, and thank you all for joining us on today's conference call. This morning, we issued our earnings press release, providing a corporate update and details of the Company's financial results for the second quarter of 2024. The release crossed the wire a short time ago and is available
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
